James Samuel Brown Iii, M D | |
100 Walker Way, Starkville, MS 39759-6607 | |
(662) 320-6555 | |
(662) 320-6566 |
Full Name | James Samuel Brown Iii |
---|---|
Gender | Male |
Speciality | Ophthalmology |
Experience | 27 Years |
Location | 100 Walker Way, Starkville, Mississippi |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1336231489 | NPI | - | NPPES |
00126317 | Medicaid | MS |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207W00000X | Ophthalmology | 16037 (Mississippi) | Primary |
Entity Name | James S. Brown, Iii, Md, Pllc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1689703324 PECOS PAC ID: 0446284921 Enrollment ID: O20050923000488 |
News Archive
Australia's reputation for excellence in cancer research has been strengthened with the launch of the Peter MacCallum Pfizer Translational Oncology Research Collaborative Hub (TORCH) at the Peter MacCallum Cancer Centre, by the Minister for Innovation, Industry, Science and Research, Senator the Hon. Kim Carr.
A study by researchers at the University of Granada has demonstrated that mortality among cyclists varies widely depending on the age and sex of the population. Male cyclists, above all those aged between 15 and 24 years, are more likely to die than adults (25-34 years), which could be explained by their greater exposure and risk of having an accident.
The White House staff continues its tireless work on health care reform as President Obama vacations on Martha's Vineyard, The New York Times reports.
Savient Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's Biologics License Application (BLA) for pegloticase, a novel biological drug for treatment-failure gout (TFG) patients.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
James Samuel Brown Iii, M D 100 Walker Way, Starkville, MS 39759-6607 Ph: (662) 320-6555 | James Samuel Brown Iii, M D 100 Walker Way, Starkville, MS 39759-6607 Ph: (662) 320-6555 |
News Archive
Australia's reputation for excellence in cancer research has been strengthened with the launch of the Peter MacCallum Pfizer Translational Oncology Research Collaborative Hub (TORCH) at the Peter MacCallum Cancer Centre, by the Minister for Innovation, Industry, Science and Research, Senator the Hon. Kim Carr.
A study by researchers at the University of Granada has demonstrated that mortality among cyclists varies widely depending on the age and sex of the population. Male cyclists, above all those aged between 15 and 24 years, are more likely to die than adults (25-34 years), which could be explained by their greater exposure and risk of having an accident.
The White House staff continues its tireless work on health care reform as President Obama vacations on Martha's Vineyard, The New York Times reports.
Savient Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's Biologics License Application (BLA) for pegloticase, a novel biological drug for treatment-failure gout (TFG) patients.
› Verified 2 days ago
Dr. George G Walker, Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 102 West Lampkin St, Starkville, MS 39759 Phone: 662-323-3941 Fax: 662-323-3942 |